356 related articles for article (PubMed ID: 10472531)
21. Apoptotic signaling pathways induced by acute administration of branched-chain amino acids in an animal model of maple syrup urine disease.
Vilela TC; Scaini G; Furlanetto CB; Pasquali MA; Santos JP; Gelain DP; Moreira JC; Schuck PF; Ferreira GC; Streck EL
Metab Brain Dis; 2017 Feb; 32(1):115-122. PubMed ID: 27510712
[TBL] [Abstract][Full Text] [Related]
22. Urinary biomarkers of oxidative damage in Maple syrup urine disease: the L-carnitine role.
Guerreiro G; Mescka CP; Sitta A; Donida B; Marchetti D; Hammerschmidt T; Faverzani J; Coelho Dde M; Wajner M; Dutra-Filho CS; Vargas CR
Int J Dev Neurosci; 2015 May; 42():10-4. PubMed ID: 25680940
[TBL] [Abstract][Full Text] [Related]
23. Maple syrup urine disease: clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity.
Korein J; Sansaricq C; Kalmijn M; Honig J; Lange B
Int J Neurosci; 1994 Nov; 79(1-2):21-45. PubMed ID: 7744549
[TBL] [Abstract][Full Text] [Related]
24. Antioxidant administration prevents memory impairment in an animal model of maple syrup urine disease.
Scaini G; Teodorak BP; Jeremias IC; Morais MO; Mina F; Dominguini D; Pescador B; Comim CM; Schuck PF; Ferreira GC; Quevedo J; Streck EL
Behav Brain Res; 2012 May; 231(1):92-6. PubMed ID: 22433584
[TBL] [Abstract][Full Text] [Related]
25. Intravenous administration of a branched-chain amino-acid-free solution in children and adults with acute decompensation of maple syrup urine disease: a prospective multicentre observational study.
Alili JM; Berleur MP; Husson MC; Mention K; Schiff M; Arnoux JB; Brassier A; Guemman AS; Grisel C; Dubois S; Abi-Wardé MT; Broissand C; Servais A; Dao M; de Lonlay P
Orphanet J Rare Dis; 2022 May; 17(1):202. PubMed ID: 35578286
[TBL] [Abstract][Full Text] [Related]
26. Diurnal changes in plasma amino acids in maple syrup urine disease.
Schwahn B; Wendel U; Schadewaldt P; Falkenberg N; Mönch E
Acta Paediatr; 1998 Dec; 87(12):1245-6. PubMed ID: 9894823
[TBL] [Abstract][Full Text] [Related]
27. Dietary supplementation of branched-chain amino acids increases muscle net amino acid fluxes through elevating their substrate availability and intramuscular catabolism in young pigs.
Zheng L; Zuo F; Zhao S; He P; Wei H; Xiang Q; Pang J; Peng J
Br J Nutr; 2017 Apr; 117(7):911-922. PubMed ID: 28446262
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and treatment of maple syrup disease: a study of 36 patients.
Morton DH; Strauss KA; Robinson DL; Puffenberger EG; Kelley RI
Pediatrics; 2002 Jun; 109(6):999-1008. PubMed ID: 12042535
[TBL] [Abstract][Full Text] [Related]
29. Branched-chain amino acids (BCAA) administration increases autophagy and the autophagic pathway in brain tissue of rats submitted to a Maple Syrup Urine Disease (MSUD) protocol.
Fermo KT; da Silva Lemos I; Farias HR; Rosso MP; Effting PS; Leipnitz G; Streck EL
Metab Brain Dis; 2023 Jan; 38(1):287-293. PubMed ID: 36305998
[TBL] [Abstract][Full Text] [Related]
30. Removal of branched-chain amino acids by peritoneal dialysis, continuous arteriovenous hemofiltration, and continuous arteriovenous hemodialysis in rabbits: implications for maple syrup urine disease treatment.
Gouyon JB; Desgres J; Mousson C
Pediatr Res; 1994 Mar; 35(3):357-61. PubMed ID: 8190527
[TBL] [Abstract][Full Text] [Related]
31. Living related versus deceased donor liver transplantation for maple syrup urine disease.
Feier F; Schwartz IV; Benkert AR; Seda Neto J; Miura I; Chapchap P; da Fonseca EA; Vieira S; Zanotelli ML; Pinto e Vairo F; Camelo JS; Margutti AV; Mazariegos GV; Puffenberger EG; Strauss KA
Mol Genet Metab; 2016 Mar; 117(3):336-43. PubMed ID: 26786177
[TBL] [Abstract][Full Text] [Related]
32. Determination of R- and S-3-methyl-2-oxopentanoate enantiomers in human plasma: suitable method for label enrichment analysis.
Schadewaldt P; Wendel U; Hammen HW
J Chromatogr B Biomed Appl; 1996 Jul; 682(2):209-18. PubMed ID: 8844412
[TBL] [Abstract][Full Text] [Related]
33. Maple syrup urine disease: interrelations between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination.
Treacy E; Clow CL; Reade TR; Chitayat D; Mamer OA; Scriver CR
J Inherit Metab Dis; 1992; 15(1):121-35. PubMed ID: 1583867
[TBL] [Abstract][Full Text] [Related]
34. Clearance of branched chain amino acids by peritoneal dialysis in maple syrup urine disease.
McMahon Y; MacDonnell RC
Adv Perit Dial; 1990; 6():31-4. PubMed ID: 1982835
[TBL] [Abstract][Full Text] [Related]
35. Intermittent branched chain ketonuria (variant of maple syrup urine disease).
Irwin WC; Martel SB; Goluboff N
Clin Biochem; 1971 Jun; 4(2):52-8. PubMed ID: 5128296
[No Abstract] [Full Text] [Related]
36. Production and characterization of murine models of classic and intermediate maple syrup urine disease.
Homanics GE; Skvorak K; Ferguson C; Watkins S; Paul HS
BMC Med Genet; 2006 Mar; 7():33. PubMed ID: 16579849
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification.
Heldt K; Schwahn B; Marquardt I; Grotzke M; Wendel U
Mol Genet Metab; 2005 Apr; 84(4):313-6. PubMed ID: 15781191
[TBL] [Abstract][Full Text] [Related]
38. Phenylbutyrate therapy for maple syrup urine disease.
Brunetti-Pierri N; Lanpher B; Erez A; Ananieva EA; Islam M; Marini JC; Sun Q; Yu C; Hegde M; Li J; Wynn RM; Chuang DT; Hutson S; Lee B
Hum Mol Genet; 2011 Feb; 20(4):631-40. PubMed ID: 21098507
[TBL] [Abstract][Full Text] [Related]
39. Hypervalinemia and hyperleucine-isoleucinemia caused by mutations in the branched-chain-amino-acid aminotransferase gene.
Wang XL; Li CJ; Xing Y; Yang YH; Jia JP
J Inherit Metab Dis; 2015 Sep; 38(5):855-61. PubMed ID: 25653144
[TBL] [Abstract][Full Text] [Related]
40. Adipose transplant for inborn errors of branched chain amino acid metabolism in mice.
Zimmerman HA; Olson KC; Chen G; Lynch CJ
Mol Genet Metab; 2013 Aug; 109(4):345-53. PubMed ID: 23800641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
